Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated, indicating potential legal matters that may affect the company [1] Company Summary - Cytokinetics, Incorporated is listed on NASDAQ under the ticker symbol CYTK [1]

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud that affected investors between December 27, 2023, and May 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten [2]. - Defendants indicated that they expected FDA approval for aficamten in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [2]. - On May 6, 2025, it was revealed during an earnings call that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Investor Information - Investors who suffered losses in Cytokinetics during the relevant period have until November 17, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have resulted in financial losses for shareholders [2]. Group 1: Company Overview - Cytokinetics, Inc. is a biopharmaceutical company focused on developing first-in-class muscle activators and next-in-class muscle inhibitors aimed at treating diseases that compromise muscle performance [1]. Group 2: Allegations and Legal Proceedings - The lawsuit claims that during the class period from December 27, 2023, to May 6, 2025, Cytokinetics made materially false statements about the expected approval timeline for aficamten's NDA, which was anticipated in the second half of 2025 based on a PDUFA date of September 26, 2025 [2]. - The company allegedly failed to disclose significant risks related to its submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process [2]. - Shareholders experienced financial losses when the true situation regarding the NDA submission was revealed [2]. Group 3: Participation in Class Action - Shareholders interested in serving as lead plaintiffs must submit their papers by November 17, 2025, and can choose to remain absent class members if they do not wish to participate [3].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated ("Cytokinetics†or the "Company†) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the "Class Period†). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion. IF YOU SUF. ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...

NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. ...

LOS ANGELES--(BUSINESS WIRE)---- $CYTK--CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm. ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- What’s H ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cytokinetics, Incorporated ("Cytokinetics†or the "Company†) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the "Class Period†). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK), CONTACT THE LAW. ...

Core Viewpoint - Cytokinetics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the New Drug Application (NDA) for aficamten, which may have caused financial losses for investors [1][3]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Cytokinetics securities between December 27, 2023, and May 6, 2025, with a deadline for filing a lead plaintiff motion set for November 17, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Cytokinetics - The complaint alleges that during the class period, Cytokinetics made materially false and misleading statements about the NDA submission and approval timeline for aficamten, specifically expecting FDA approval in the second half of 2025 [3]. - The company failed to disclose significant risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to financial losses for shareholders when the truth was revealed [3].